Search results for " Type 1"

showing 10 items of 430 documents

The influence of local capsaicin treatment on small nerve fibre function and neurovascular control in symptomatic diabetic neuropathy.

2002

Topical treatment with capsaicin cream has been shown to be successful in the treatment of different symptomatic nerve disorders like diabetic neuropathy. Conflicting data exist on the effect of capsaicin on nerve function and neurovascular control especially in patients with diabetic neuropathy. The aim of this pilot study was to investigate the impact of topical capsaicin application on small nerve fibre function and neurovascular control. Capsaicin cream was applied to the feet of 13 patients with symptomatic diabetic neuropathy over a period of 8 weeks. Before and during the treatment period, we investigated the total symptoms score, the vibration, thermal (heat and cold) and pain perce…

MaleDiabetic neuropathyEndocrinology Diabetes and MetabolismAdministration TopicalSubstance PPilot Projectschemistry.chemical_compoundRoute of administrationEndocrinologyNerve FibersDiabetic NeuropathiesInternal MedicineMedicineHumansbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseNeurovascular bundlePeripheral neuropathymedicine.anatomical_structureDiabetes Mellitus Type 1chemistryDiabetes Mellitus Type 2CapsaicinAnesthesiaSensory ThresholdsNociceptorFemaleCapsaicinbusinessSensory nervePhytotherapyActa diabetologica
researchProduct

Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors2 Centimeters.

2019

Abstract Purpose Pancreatic neuroendocrine tumors (pNETs) are frequent in multiple endocrine neoplasia type 1 (MEN1) syndrome. They are usually not surgically treated unless larger than 1 to 2 cm or a growth rate > 0.5 cm per year. Somatostatin analogues represent one of the main therapeutic options in pNETs, but they have never been prospectively investigated in MEN1-related pNETs. The aim of this study was to prospectively evaluate the effectiveness of lanreotide in patients with MEN1-related pNETs < 2 cm. Methods MEN1 patients with 1 or more pNETs < 2 cm of maximal diameter were considered. Study design was prospective observational, comparing patients treated with l…

MaleEndocrinology Diabetes and MetabolismClinical BiochemistryNeuroendocrine tumorsLanreotideBiochemistryGastroenterologychemistry.chemical_compoundEndocrinologyactive surveillance lanreotide MEN1 pancreatic neuroendocrine tumors somatostatin analoguesProspective StudiesProspective cohort studyMultiple endocrine neoplasiasomatostatin analoguesMiddle AgedPrognosisTumor BurdenNeuroendocrine TumorsSomatostatinMEN1Disease ProgressionFemalelanreotideSomatostatinAdultmedicine.medical_specialtyAntineoplastic Agentspancreatic neuroendocrine tumorPeptides CyclicYoung AdultInternal medicinemedicineMultiple Endocrine Neoplasia Type 1HumansMEN1Watchful WaitingAgedCentimeterpancreatic neuroendocrine tumorsbusiness.industryBiochemistry (medical)active surveillancemedicine.diseasePancreatic NeoplasmsEndocrinologychemistryactive surveillance; lanreotide; MEN1; pancreatic neuroendocrine tumors; somatostatin analoguesTumor progressionCase-Control StudiesbusinessFollow-Up StudiesThe Journal of clinical endocrinology and metabolism
researchProduct

Association between symptoms of depression, diabetes complications and vascular risk factors in four European cohorts of individuals with type 1 diab…

2020

Aims: To investigate the association between depressive symptomatology and health markers in type 1 diabetes. Methods: Four countries from the InterDiane Consortium had adopted the Finnish Diabetic Nephropathy Study protocol, including the Beck Depression Inventory (BDI). Associations between depression symptomatology, diabetes complications (diabetic nephropathy, proliferative retinopathy, major adverse cardiovascular events [MACE]) and vascular risk factors (metabolic syndrome, body mass index, glycaemic control) were investigated. Results: In a sample of 1046 participants (Croatia n = 99; Finland n = 314; Latvia n = 315; Lithuania n = 318), 13.4% displayed symptoms of depression (BDI sco…

MaleEndocrinology Diabetes and MetabolismDISEASEDiabetic nephropathy0302 clinical medicineEndocrinologyRisk FactorsGLYCEMIC CONTROLSurveys and QuestionnairesPrevalence030212 general & internal medicineDepression (differential diagnoses)2. Zero hungerDepressionGeneral MedicineMiddle AgedMetabolic syndrome3. Good healthEuropeType 1 diabetesFemaleHEALTHAdultmedicine.medical_specialty030209 endocrinology & metabolismRETINOPATHYDiabetes Complications03 medical and health sciencesInternal medicineDiabetes mellitusInternal MedicinemedicineHumansVascular DiseasesType 1 diabetesbusiness.industry616.379-008.64 [udc]Beck Depression InventoryADULTSCAREmedicine.diseaseCross-Sectional StudiesDiabetes Mellitus Type 13121 General medicine internal medicine and other clinical medicineDepression ; Diabetes complications ; Metabolic syndrome ; Type 1 diabetesDiabetes mellitus type 1 ; psychology ; Depression ; Diabetes complications ; Metabolic syndrome ; Cross-sectional studiesSelf ReportMetabolic syndromebusinessBody mass indexMace
researchProduct

L-NAME induces direct arteriolar leukocyte adhesion, which is mainly mediated by angiotensin-II.

2005

Acute inhibition (1 h) of nitric oxide synthase (NOS) with L-NAME causes leukocyte recruitment in the rat mesenteric postcapillary venules that is angiotensin-II (Ang-II) dependent. Since 4-h exposure to Ang-II provokes arteriolar leukocyte adhesion, this study was designed to investigate whether subacute (4-h) NOS inhibition also causes this effect.Rats were intraperitoneally injected with saline, L-NAME, or 1H-[1,2,4]-oxidazolol-[4,3-a]-quinoxalin-1-one (ODQ). Leukocyte accumulation in the mesenteric microcirculation was examined 4 h later via intravital microscopy. Some groups were pretreated with losartan, an AT(1) Ang-II receptor antagonist.At 4-h, L-NAME caused a significant increase …

MaleEndotheliumPhysiologyPharmacologyLosartanNitric oxideRats Sprague-Dawleychemistry.chemical_compoundVenulesPhysiology (medical)medicineCell AdhesionLeukocytesAnimalsLeukocyte RollingSplanchnic CirculationReceptorMolecular BiologyAngiotensin II receptor type 1Microscopy VideobiologyAngiotensin IIAngiotensin IIRatsNitric oxide synthaseArteriolesmedicine.anatomical_structureLosartanNG-Nitroarginine Methyl EsterchemistryImmunologycardiovascular systembiology.proteinNitric Oxide SynthaseCardiology and Cardiovascular MedicineCell Adhesion MoleculesIntravital microscopymedicine.drugMicrocirculation (New York, N.Y. : 1994)
researchProduct

Metformin and health outcomes:An umbrella review of systematic reviews with meta-analyses

2021

Background:\ud \ud The objective was to capture the breadth of outcomes that have been associated with metformin use and to systematically assess the quality, strength and credibility of these associations using the umbrella review methodology.\ud \ud Methods:\ud \ud Four major databases were searched until 31 May 2020. Meta‐analyses of observational studies and meta‐analyses of randomized controlled trials (RCTs) (including active and placebo control arms) were included.\ud \ud Results:\ud \ud From 175 eligible publications, we identified 427 different meta‐analyses, including 167 meta‐analyses of observational studies, 147 meta‐analyses of RCTs for metformin vs placebo/no treatment and 11…

MaleGRADE meta-analysis metformin umbrellamedicine.medical_specialtyPregnancy Rateendocrine system diseasesClinical Biochemistry030204 cardiovascular system & hematologyOverweightBiochemistryBody Mass Indexlaw.invention03 medical and health sciences0302 clinical medicineMeta-Analysis as TopicRandomized controlled trialPregnancylawNeoplasmsInternal medicinemedicineHumansHypoglycemic AgentsObesity030212 general & internal medicinePrediabetesbusiness.industryGeneral MedicineOverweightProtective Factorsmedicine.diseaseMetforminMetforminDiabetes Mellitus Type 1Systematic reviewDiabetes Mellitus Type 2Cardiovascular DiseasesMeta-analysisFemaleObservational studymedicine.symptombusinessInfertility FemaleBody mass indexPolycystic Ovary SyndromeSystematic Reviews as Topicmedicine.drug
researchProduct

Being hospitalized with a newly diagnosed chronic illness - A phenomenological study of children’s lifeworld in the hospital

2012

The impact of a hospital environment on children has rarely been investigated. Recently, however, the perspective of hospitalized children has been taken into account. Being hospitalized and facing an illness represent a dramatic change in a child’s daily life, and the quality of the environment may influence the child’s experiences. The aim of this study was to investigate the experiences of children being hospitalized with newly diagnosed type 1 diabetes and to obtain an increased understanding of the environmental influences on the children’s lifeworld. The study used a hermeneutic phenomenological approach. The design is a combination of observation of the participant, interviews, and p…

MaleGerontologyHealth Knowledge Attitudes Practicemedicine.medical_specialtyLifeworldtype 1 diabetesmedia_common.quotation_subjectNewly diagnosedNursingbodily changeshospital environmentInterviews as TopicVDP::Medical disciplines: 700::Health sciences: 800::Nursing science: 808Empirical StudiesPerceptionAdaptation PsychologicalVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Pediatrics: 760HumansLearningMedicineChildPsychiatrymedia_commonEnvironment method hospitalised children lived experience type 1 diabetesbusiness.industryHealth PolicyLived experiencePerspective (graphical)Peer reviewIssues ethics and legal aspectsAlertnessDiabetes Mellitus Type 1hermeneutic phenomenological methodChronic DiseaseHealth Facility Environmentlived experienceFemaleFundamentals and skillsHospitalized childrenThematic analysisbusinessChild HospitalizedGerontologyInternational Journal of Qualitative Studies on Health and Well-being
researchProduct

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-…

2017

Background Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor approved for the treatment of type 2 diabetes. We aimed to assess the efficacy and safety of dapagliflozin as an add-on to adjustable insulin in patients with inadequately controlled type 1 diabetes. Methods DEPICT-1 was a double-blind, randomised, parallel-controlled, three-arm, phase 3, multicentre study done at 143 sites in 17 countries. Eligible patients were aged 18–75 years and had inadequately controlled type 1 diabetes (HbA1c between ≥7·7% and ≤11·0% [≥61·0 mmol/mol and ≤97·0 mmol/mol]) and had been prescribed insulin for at least 12 months before enrolment. After an 8 week lead-in period to optimise diabetes man…

MaleGlycated Hemoglobin AEndocrinology Diabetes and MetabolismType 2 diabetes030204 cardiovascular system & hematologySettore MED/13 - Endocrinologialaw.inventionchemistry.chemical_compound0302 clinical medicineEndocrinologydiabetes dapaglifozinGlucosidesRandomized controlled triallawInsulin03.02. Klinikai orvostanDapagliflozinMiddle AgedDiabetes and MetabolismTreatment OutcomeCombinationDrug Therapy CombinationFemaleType 1Adultmedicine.medical_specialtyDiabetic ketoacidosis030209 endocrinology & metabolismPlacebo03 medical and health sciencesDrug TherapyDiabetes managementDiabetes mellitusInternal medicineDiabetes MellitusInternal MedicinemedicineHumansHypoglycemic AgentsBenzhydryl CompoundsAdult; Benzhydryl Compounds; Body Weight; Diabetes Mellitus Type 1; Drug Therapy Combination; Female; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Treatment OutcomeAdult; Benzhydryl Compounds; Body Weight; Diabetes Mellitus Type 1; Drug Therapy Combination; Female; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Treatment Outcome; Internal Medicine; Endocrinology Diabetes and Metabolism; EndocrinologyGlycated HemoglobinType 1 diabetesbusiness.industryBody Weightmedicine.diseaseHypoglycemiaSurgeryDiabetes Mellitus Type 1chemistrybusinessThe Lancet Diabetes & Endocrinology
researchProduct

Killer cell immunoglobulin-like receptor genes in Latvian patients with type 1 diabetes mellitus and healthy controls.

2004

T1DM is very common in Sweden and is positively associated with HLA class II genes. Approximately 89% of the newly diagnosed patients carry the high-risk HLA DR4-DQ8 and DR3-DQ2. The remaining 11% develop T1DM without them. This can be due to involvement of other genes and environmental factors. Natural killer (NK) cells of the innate immune system are important in antiviral and antitumor immunity. They are implicated in the etiology of autoimmune T1DM. Human NK cells express killer cell immunoglobulin-like receptors (KIR) that belong to the polymorphic multigene family in chromosome 19q3.4. They modulate NK cell response by interacting with HLA class I. In addition, polymorphic MICA in HLA…

MaleKiller-cell immunoglobulin-like receptorHuman leukocyte antigenBiologyGeneral Biochemistry Genetics and Molecular BiologyHistory and Philosophy of ScienceGene FrequencyReceptors KIRimmune system diseasesPolymorphism (computer science)HumansAlleleReceptors ImmunologicReceptorAllele frequencyAllelesInnate immune systemPolymorphism GeneticGeneral NeuroscienceHistocompatibility Antigens Class Inutritional and metabolic diseasesAcquired immune systemLatviaKiller Cells NaturalDiabetes Mellitus Type 1Gene Expression RegulationCase-Control StudiesReceptors KIR2DL2ImmunologyFemaleChromosomes Human Pair 19Microsatellite RepeatsAnnals of the New York Academy of Sciences
researchProduct

Parent-adolescent conflict, treatment adherence and glycemic control in Type 1 diabetes: the importance of adolescent externalising symptoms.

2013

Parent-adolescent conflict has been demonstrated to relate to treatment adherence and glycemic control in adolescents with Type 1 diabetes. The present longitudinal study investigated how these variables were interrelated over time, and examined whether externalising and internalising symptoms function as mediating variables. A total of 109 adolescents with diabetes participated at four annual time points and completed measures on conflict with parents, internalising and externalising symptoms. Information on treatment non-adherence and glycemic control was obtained from treating physicians. Cross-lagged analyses from a structural equation modelling approach indicated that father-adolescent…

MaleLongitudinal studyTime FactorsAdolescentTreatment adherenceControl (management)Models PsychologicalStructural equation modelingDevelopmental psychologyConflict PsychologicalDiabetes mellitusmedicineHumansLongitudinal StudiesParent-Child RelationsChildApplied PsychologyGlycemicGlycated HemoglobinType 1 diabetesPublic Health Environmental and Occupational HealthGeneral MedicineGeneral Chemistrymedicine.diseaseSelf CareDiabetes Mellitus Type 1Adolescent BehaviorPatient ComplianceFemalePsychologyPsychologyhealth
researchProduct

Low Rate of Virological Failure and Maintenance of Susceptibility to HIV-1 Protease Inhibitors with First-Line Lopinavir/Ritonavir-Based Antiretrovir…

2010

Protease inhibitor (PI)-resistant HIV-1 has hardly ever been detected at failed boosted PI-based first-line antiretroviral regimens in clinical trials. However, this phenomenon has not been investigated in clinical practice. To address this gap, data from patients starting a first-line lopinavir/ritonavir (LPV/rtv)-based therapy with available baseline HIV-1 RNA load, a viral genotype and follow-up viral load after 3 and 6 months of treatment were extracted from the Italian Antiretroviral Resistance Cohort Analysis (ARCA) observational database. Based on survival analysis, 39 (7.1%) and 43 (7.8%) of the 548 examined patient cases had an HIV-1 RNA >500 and >50 copies/ml, respectively, after …

MaleLopinavir/ritonavirHIV Infectionsboosted protease inhibitorLopinavirCohort Studies0302 clinical medicineAntiretroviral Therapy Highly Activevirologic failureHIV InfectionTreatment Failure030212 general & internal medicinePyrimidinone0303 health scienceseducation.field_of_studylopinavir/ritonavirLopinavirViral LoadResistance mutationfirst-line antiretroviral therapyReverse Transcriptase Inhibitor3. Good healthTreatment OutcomeInfectious DiseasesRNA ViralReverse Transcriptase InhibitorsMedicineDrug Therapy CombinationFemaleSurvival AnalysiViral loadHumanmedicine.drugAnti-HIV AgentsPopulationPyrimidinones.Settore MED/17 - MALATTIE INFETTIVEEmtricitabinehuman immunodeficiency virus type 103 medical and health sciencesVirologyDrug Resistance Viralantiretroviral drug resistancemedicineHumansProtease inhibitor (pharmacology)educationHIV Protease InhibitorRitonavir030306 microbiologybusiness.industryAnti-HIV AgentHIV Protease InhibitorsSurvival AnalysisVirologyHIV-1RitonavirCohort Studiebusiness
researchProduct